Effects of oral anticoagulant therapy on gene expression in crosstalk between osteogenic progenitor cells and endothelial cells
| Autor: | Michela Deiana, Maria Teresa Valenti, Silvia Suardi, Samuele Cheri, Anna Brunelli, Luca Dalle Carbonare, Monica Mottes |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
CD31
anticoagulants Angiogenesis lcsh:Medicine 030204 cardiovascular system & hematology Article osteogenesis 03 medical and health sciences 0302 clinical medicine N-terminal telopeptide Medicine circulating progenitors gene expression Progenitor cell 030304 developmental biology 0303 health sciences business.industry Mesenchymal stem cell lcsh:R Bone Marrow Stem Cell General Medicine medicine.anatomical_structure Cancer research Liver function Bone marrow business |
| Zdroj: | Journal of Clinical Medicine Journal of Clinical Medicine, Vol 8, Iss 3, p 329 (2019) Volume 8 Issue 3 |
| Popis: | Direct oral anti-coagulants (DOACs) are employed in clinical practice for the prevention and treatment of recurrent venous thromboembolism and for the prevention of stroke in non-valvular atrial fibrillation. DOACs directly and reversibly inhibit activated factor X or thrombin and can interfere with other pathophysiological processes such as inflammation, lipid metabolism, and bone turnover. We aimed to evaluate the possible effects of DOACs on osteogenesis and angiogenesis. We treated 34 patients affected by cardiovascular disorders with DOACs biochemical and molecular analyses were performed before and after three months of treatment. Circulating progenitors (CPs CD34&minus CD45&minus CD14&minus CD73+, CD105+), which share typical bone marrow stem cell (MSCs) features, were harvested from peripheral blood of the study subjects to monitor the expression of osteogenesis-related genes RUNX2 and SPARC. Human umbilical vein endothelial cells (HUVECs) were used to probe angiogenesis-related VEGF, CD31, and CD105 gene expression. We performed co-culture experiments using a commercial human mesenchymal stem cells line (hMSCs) obtained from bone marrow and HUVECs. Clinical parameters related to bone metabolism, coagulation, renal and liver function, and the lipid profile were evaluated. Values of the C-terminal telopeptide type I collagen (CTX) increased after the treatment. We found a significant increase in osteogenesis marker gene expression in CPs after three months of anticoagulant therapy. An increase in the RUNX2 expression determinant alone was detected instead in hMSCs co-cultured with HUVECs in the presence of treated patients&rsquo sera. The VEGF, CD31, and CD105 marker genes appeared to be significantly upregulated in HUVECs co-cultured with hMSCs in the presence of treated patients&rsquo sera. Under these conditions, new vessel formation increased as well. Our results highlight an unexpected influence of DOAC therapy on osteogenic commitment and vascular endothelial function promotion. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|